BG
CRSP icon

Berry Group’s CRISPR Therapeutics CRSP Stock Holding History

Berry Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$421K Buy
2,751
+51
+2% +$6.03K 0.19% 77
2020
Q3 		$226K Buy
+2,700
New +$240K 0.12% 103

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Berry Group's CRSP Position: Q4 2020 in Review

Berry Group increased its CRISPR Therapeutics (CRSP) stake by 1.9% in Q4 2020, buying an estimated $6.03K and bringing the position to 2,751 shares worth $421K. The position accounts for 0.19% of the portfolio, ranked #77.

Berry Group first reported a position in CRSP in Q3 2020 and has held it in 2 quarters since. 412 funds tracked by Wall St. Rank hold CRSP as of Q4 2020.

  • Berry Group held 2,751 shares of CRISPR Therapeutics worth $421K as of Q4 2020.
  • Berry Group bought 51 CRISPR Therapeutics shares in Q4 2020, an estimated $6.03K.
  • CRISPR Therapeutics made up 0.19% of Berry Group's portfolio in Q4 2020, its #77 holding.
  • Berry Group first reported a position in CRISPR Therapeutics in Q3 2020 and has held it in 2 quarters since.
  • 412 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2020.

Based on Berry Group's 13F filing for Q4 2020, filed 11 Feb 2021.